Workshops and Symposia

DT 2016 picturePreliminary results of safety and feasibility for suppressing focal epilepsy with GTEN neuromodulation

Brain Stimulation and Imaging Meeting
KeyNote Address - Don Tucker, PhD
Vancouver Marriott Pinnacle Downtown Hotel
1128 West Hastings Street
Vancouver, BC, Canada

Saturday, 24 Jun, 2017
10:45 am
Pinnacle Ballroom

In this talk, Don Tucker, CEO of Electrical Geodesics, Inc., presented preliminary results of case studies from the first three patients treated in its safety and feasibility trial for suppressing focal epilepsy with Geodesic Transcranial Electrical Neuromodulation (GTEN).

The patients in this trial at the University of Washington Harborview Hospital in Seattle suffer from focal epilepsy (i.e., epilepsy associated with a specific region of the brain) that is not controlled by medication. The epileptic discharges reflect the abnormal activity of the brain that is often associated with generating seizures. Each of the three patients demonstrated a significant suppression of interictal spikes immediately following treatment, compared to the rate before treatment across the five treatment days.

GTEN technology represents an advance in targeting brain regions for electrical neuromodulation with a dense electrode array (256 channels) distributed over the head surface, and with high performance computing applied to model the distribution of electrical current in each patient's head tissues. EGI's proprietary technology allows the use of the patient's dense array electroencephalography (dEEG) to guide the targeting of the therapeutic pulses of electric current.

Questions? Contact EGI Workshops.

See all posters and talks presented at OHBM and Brain Stimulation and Imaging from EGI and collaborators.

High-Resolution Electrical Head Models for Dense Array Neuromodulation

OHBM 2017 Vancouver Blue Square smallEGI Lunch Symposium at OHBM 2017
Vancouver Convention Centre
999 Canada Pl
Vancouver, BC, Canada

Tuesday, 27 June 2017
Room 220-222, Level 2

SymposiaOnDemand button
Missed this symposium? See it now with SYMPOSIA OnDemand!

EGI's new Geodesic Transcranial Electrical Neuromodulation (GTEN) technology integrates EGI's core GES 400 dEEG platform and its proprietary head modeling technology to create a precise method for tDCS/tACS/tPCS neuromodulation tailored for the individual.

In this symposium, a bounded electrical impedance tomography (bEIT) approach was presented for individually specific calibration of high-resolution electrical head models. bEIT is used to estimate the most important electrically resistive tissue (the skull) of the head. The resulting calibrated, anatomically accurate, electrical head model is then used for EEG source estimation and transcranial electrical stimulation (TES) planning. Based on EEG source estimation, targets are defined for TES and simultaneously recorded EEG can be examined to assess the brain’s response to the stimulation.


Sergei Turovets, PhD, Scientist, Electrical Geodesics, Inc.
A bounded electrical impedance tomography (bEIT) approach to calibration of individual electrical head models.

Don Tucker, PhD, and Erik Anderson, PhD, Electrical Geodesics, Inc.
Targeting with GTEN and Evaluating EEG Responses.

Lyubomir Zagorchev, PhD, Senior Scientist, Philips Neuro Diagnostics 
Brain segmentation for quantitative disease biomarkers and patient-specific care. 

Questions? Contact EGI Workshops.

See all posters and talks at OHBM and Brain Stimulation and Imaging from EGI and collaborators.

Mintz webinarHigh Density EEG

Recorded Webinar
Organized by ASET – The Neurodiagnostic Society

In High Density EEG, a large number (>120) of saline soaked sensors record the electrical activity of the brain. This presentation will explain the research as well as clinical applications of high density EEG and its accuracy in detecting abnormalities.

View this webinar online at the ASET website.
$25 for ASET members
$40 for non-members

After you purchase the webinar, you will receive a link to the recording.


Mark Mintz, MD is President, CEO, and Founder of The Center for Neurological and Neurodevelopmental Health (CNNH), and the Clinical Research Center of New Jersey (CRCNJ). Dr. Mintz has been an advocate for transforming health care delivery systems for special needs populations, which has led to the creation of the innovative and unique “Specialty Care Medical Home®” model utilized at CNNH.

Providing access to innovative diagnostic and treatment services, CNNH has been one of the leading clinical providers of High Density EEG (HD-EEG). Thus, Dr. Mintz has extensive experience in employing HD-EEG in clinical practice for various populations across the lifespan, and has reported on extremely high acquisition rates in neurobehaviorally challenged populations without sedation or restraint. Dr. Mintz has also organized workshops on the interpretation and clinical applications of HD-EEG, and has presented data on clinical and neuropsychological abnormalities related to “unexpected subclinical spikes” in patients with ADHD, Learning and Neurodevelopmental Disorders.

Dr. Mintz is quadruple board certified in Neurology (with special qualification in Child Neurology), Neurodevelopmental Disabilities, Epilepsy and Pediatrics. Dr. Mintz is widely published in the medical literature, is on the editorial boards of peer-reviewed journals, has been an invited lecturer at a large number of national and international conferences, and has been a neurology board examiner. He functions as the principal investigator on a variety of original research grants, clinical drug trials, and other research studies. Additionally, Dr. Mintz has served in the National Health Service Corps of the United States Public Health Service, and has volunteered for medical relief missions in Romania and Russia.